<DOC>
	<DOCNO>NCT01079546</DOCNO>
	<brief_summary>The rationale study proposal derive previous case series demonstrate 60 % patient HNSCC , especially oropharynx associate high risk HPV infection . In study , characterize association HPV infection HNSCC Israel establish program diagnosis management base HPV biomarker . The rationale propose research know type HPV associate HNSCC , information use direct diagnosis screen effort high risk population . Our approach base establish multicenter consortium lead researcher establish joint database demographic , clinical biological data various region Israel . For assembled multidisciplinary research team scope breath ( surgical oncology , pathology , virology molecular biology ) need complete phase research successfully . The research coordinate perform Applied Cancer Research Laboratory , Tel Aviv Sourasky Medical Center . The patient recruit 7 tertiary medical center Israel : Ichilov , Bellinson , Hadassa , Rambam , Soroka , Sheba Nazeret..</brief_summary>
	<brief_title>Human Papillomavirus ( HPV ) Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description>To determine prevalence classify high risk human papillomavirus type associate head neck cancer Israel . We determine HPV genotype distribution Israel order study ethnic uniqueness region . Many study show HPV 16 prevalent type HNSCC ( NEJM ) . In Israeli Jewish woman HPV type 16 , 39 , 52 , 18 prevalent genotype find ( 15 ) . In aim , determine prevalence various HPV genotype HNSCC specimens.Study population The group include patient treat primary surgery biopsy , without adjuvant radiotherapy 1998 2010 SCC oral cavity , oropharynx , hypopharynx , larynx paranasal sinus . The anatomic site extent primary tumor document . The TNM classification base stag system revise American Joint Committee Cancer ( AJCC ) . Patients recruit seven national cancer referral hospital , include Soroka Medical Center Negev ( Beer Sheva ) , Sourasky Medical Center ( Tel Aviv ) , Rabin Medical Center ( Petach Tikva ) , Hadassa Medical ( Jerusalem ) , Rambam Medical Center ( Haifa ) , Sheba medical center ( Ramat- Gan ) French Hospital Nazareth ( Nazareth ) . These center cover almost entire population Israel , include Israeli Jews , Bedouins , Druze Israeli Arab population . Data Entry Data enter commercially available spreadsheet ( Microsoft Excel 2000 , Microsoft Corporation , Seattle , WA ) statistical analysis perform use computerized software package ( SPSS ) . We previously use similar system report result 146 patient skull base sarcomas international multicenter study include 17 cancer center ( 17 ) . Tumor specimens Specimens collect retrospectively , comprise paraffin section primary tumor biopsy retrived pathology department archive center . Transportation paraffin block Tel Aviv deparaphinization HPV test take place personally investigator . Histopathological analysis Primary tumor specimen first evaluate pathologist participate cancer . All specimens re-analyzed evaluated head neck pathologist , Dr. Kaplan Ilana . Specimen dissection tissue sample primary tumor accordance current guideline histopathological assessment head neck cancer carcinoma . HPV detection laboratory Tissue section subject deparaffinization , heatinduced target retrieval , digestion proteinase K ( Roche Diagnostics , Indianapolis , IN ) , describe previously ( 18 ) . DNA purify paraffin deparaffinization , proteinase K digestion , phenol/chloroform extraction , ethanol precipitation . We use HPV genotyping system use PCR base HPV GenoArray test kit genotyping 37 HPV taypes ( Hybribio Limited , Hong Kong ) . Specimens place PreservCytR LBC medium ( ThinPrep liquid Pap vial ; Cytyc Corporation ) . The Amplicor HPV test kit contain pool HPV-specific primer design amplify HPV DNA 13 HR genotype ( type 16 , 18 , 31 , 33 , 35 , 39 , 45 , 51 , 52 , 56 , 58 , 59 , 68 ) . According manufacturer 's specification , Amplicor HPV test detects HPV genotypes 31 , 52 , 58 , 59 240 copies/ml HPV genotypes 16 , 18 , 33 , 35 , 39 , 45 , 51 , 56 , 68 100 copies/ml positivity rate great 95 % . All genotype detect 100 % positivity rate 480 copies/ml . HPV genotyping HPV genotyping perform use commercially available PCR base HPV GenoArray test kit ( Hybribio Limited , Hong Kong ) , make use DNA amplification HybriBio 's proprietary flowthrough hybridization technique simultaneously identify 21 HPV genotype , include 5 low-risk type ( type 6 , 11 , 42 , 43 , 44 ) , 14 HR type ( type 16 , 18 , 31 , 33 , 35 , 39 , 45 , 51 , 52 , 56 , 58 , 59 , 66 , 68 ) , 2 intermediate-risk type ( type CP8304 53 ) . The test employ macroarray format nylon membrane onto HPV genotype-specific oligonucleotides probe immobilize . In Situ Hybridization system perform Amplicor HPV test ( Roche Molecular Systems ) validation result . This kit design detection discrimination human papilloma virus ( HPV ) DNA paraffinembedded tissue . An HPV16-positive tumor specimen use positive control . p16 Immunohistochemistry The expression status p16 strongly correlate tumor HPV status ( 19 ) therefore evaluate presence protein immunohistochemistry ( 20 ) . After 5- Î¼ section deparaffinized , antigen retrieval perform use heat-induced epitope retrieval 10 mM citrate buffer . Immunostaining perform Ventana automate stainer ( Ventana Medical Systems , Tucson , AZ ) accord manufacturer 's recommendation . Cervical specimen know positive HPV use positive control normal tissue baseline control . A mouse monoclonal antibody p16 ( MTM Laboratories , Heidelberg , Germany ) 1:500 dilution utilize . The p16 antibody detect use avidin-biotin-peroxidase technique ( Dako LSAB Kit , Dako ) . On histopathologic review , pattern p16 expression generally dichotomous accord tumor sample , p16 stain either absent ( negative ) present strong diffuse nuclear cytoplasmic staining ( positive ) . Relative protein expression estimate use dedicate software ( Metamorph , Molecular Devices , Union City , CA ) , analyzed intensity area positive staining . Immunohistochemical interpretation perform two investigator blind HPV status identity patient tumor originate . Evaluation association HPV status therapeutic response survival patient oropharyngeal/laryngeal SCC Prospective analyse case series United States Europe consistently demonstrate patient oropharyngeal SCC HPV-positive good prognosis patient whose tumor HPV negative ( 21,22 ) . We evaluate effect tumor HPV status treatment response survival outcome among patient oropharyngeal laryngeal SCC treat primary chemoradiation radiation therapy ( organ preservation regime ) . Data Collection Each center collect data patient chart . The data include : age , sex , ethnic group , area birth residence , religion , education ( ever attendance school , number year school attendance , age leave school ) , long occupation , use tobacco different form , alcohol drinking habit , dietary habit , marital status , sexual history ( number lifetime sexual partner , visit prostitute , frequency oral sex ) , histories various disease , family history cancer , oral cavity health . A `` smoker '' define individual report smoke tobacco daily least 1 year , smoker ask duration smoking amount type tobacco smoke ( cigarette , cigar , pipe form tobacco chewing ) . A `` drinker '' define individual report drink alcoholic beverage least month . Details obtain type beverage , amount duration habitual drinking . information tumor-node-metastasis classification stag obtain study patient . This classification convert stage accord American Joint Committee Cancer ( AJCC ) Cancer Staging Manual . We evaluate outcome therapy term response ( complete response , partial response progressive disease accord RECIST classification ) Statistical analysis Five-year overall survival ( OS ) , disease-specific survive al ( DSS ) locoregional control rate calculate use Kaplan-Meier method difference survival rate assess log rank test ( 17 ) . OS measured date surgery date death last follow-up . For DSS , patient die cause SCC censor time death . The variable prognostic potential suggest univariate analysis subject multivariate analysis Cox proportional hazard regression model . All statistic two-sided . A value P &lt; 0.05 consider indicate statistical significance . Comparison HPV/p16 classification ( three-class model ) perform Kruskal-Wallis analysis follow Wilcoxon rank sum test Bonferroni correction . Comparison protein expression HPV/p16 classification make use one-way analysis variance ( ANOVA ) post hoc comparison Dunnett 's T3 test . Comparison HPV - three class model classification status specific clinical pathologic variable ( sex , TNM stage , T stage , N stage , histologic grade , management , radiotherapy , chemoradiation , alcohol use , tobacco use clinical response ) , perform Fisher 's exact test . Clinical response record complete response versus response/partial response completion treatment . All calculation analysis perform Statistical Package Social Sciences version 11.5 Windows ( SPSS Inc , Chicago , IL ) , qualified statistician Tel Aviv Souraky Medical Center ( Esther Shabtai PhD ) . Sample size justification The prevalence HNSCC Israel estimate 52 oropharyngeal 250 laryngeal cancer new case per year ( Middle East cancer consorcium , www.mecc.cancer.gov ) . The medical center participate study cover 80 % population State Israel . estimate participation rate among case patient 89 % ( range 76 99.0 % ) ( REF JNCI International ) . Therefore estimated study period 6 month approximately 100 sample recruit .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>SCC oral cavity , oropharynx , hypopharynx , larynx paranasal sinus . pregnancy , age &lt; 18</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>HPV , Israel , Squamous cell carcinoma head neck</keyword>
</DOC>